USPTO serial 79008059
SANOVEL
Reviewed by CopyMark Law Group
Reg. 3154206Status 404
- Filing date
- Status date
- Registration date
- Oct 10, 2006
- Examiner
- BENMAMAN, ALICE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SANOVEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
Istanbul, TR
Other trademarks owned by SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
Istanbul, TR
Other trademarks owned by SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
TR
Other trademarks owned by SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS, SKELETO-MUSCULAR DISORDERS, GENERAL INFECTIONS, VIRAL INFECTIONS, CENTRAL NERVOUS SYSTEM DISORDERS, GASTRO-INTESTINAL DISORDERS, FUNGAL DISEASES, ERECTILE DYSFUNCTION, RESPIRATORY DISEASES, ALLERGY, OPHTHALMIC DISEASES, CONTAINING ONE OR MORE OF THE FOLLOWING ACTIVE INGREDIENTS - CROMOLIN SODIUM, AMLODIPIN BESYLATE, ALENDRONATE SODIUM, CHLORAZEPATE DIPOTASSIUM, ATROPINE SULPHATE, ATORVASTATIN CALCIUM, CANDESARTAN CILEXETIL, CEFTRIAXONE SODIUM, EPHEDRINE HCL, GUAIPHENESINE, ZAFIRLUKAST, DONEPEZIL HCL, DIFLUNISAL, DIPYRIDAMOLE, FAMOTIDINE, LOSARTAN POTASSIUM, HYDRO-CHLOROTHIAZIDE, MELOXICAM, PHENYLEPRINE HCL, FEXOFENADINE HCL, INDAPAMIDE, SULFISOXAZOLE, CLOPIDOGREL, LANSOPRAZOLE, CLARITHROMYCIN, FLURBIPROFEN, NIMESULIDE, PANTOPRAZOLE, PARACETAMOLE, PILOCARPINE HCL, LISINOPRIL, PSEUDOEPHEDRINE HCL, CIPROFLOXACIN HCL, SERTRALINE HCL, CYCLOPENTOLATE HCL, DIHYDROERGOTOXINE METHANSULFONATE, TERBINAFINE, TIMOLOL MALEATE, TIAMPHENICOL, AZITHROMYCIN, TENOXICAM, FLUCONAZOLE, DIGOXINE, TIOCONAZOLE, DIMENHYDRINATE, QUINIDINE ARABOGALACTANE SULPHATE, QUINIDINE PHENYLETHYL BARBITURATE, DILTIAZEM HCL, BUSPIRONE HCL, AMIODARONE HCL, TRAZODONE, DIFLUPREDNATE, ENOXACIN, LACTULOSE, KETOROLAC, PENTOXIFYLLINE, VITAMIN E, CHLORHEXIDINE, CETRIMIDE, PROPYPHENAZONE, CAFFEINE, CETIRIZINE, PHENYLPROPANOLAMINE, ZOLPIDEM, BACAMPICILLIN HCL, ROXITHROMYCIN, SULTAMICILLIN TOSILATE, ACETYLSALICYLIC ACID, AMPICILLIN NA, SULBACTAM NA, SILDENAFIL CITRATE, AMBROXOL HCL, RIBAVIRIN, LORATADINE, ETODOLAC, OMEPRAZOLE, OXYBUTYNIN CHLORIDE, QUINIDINE SULPHATE, OLANZAPINE, RALOXIFEN, PIOGLITAZONE, MOXIFLOXACIN, ROSIGLITAZONE, SIBUTRAMIN, CARVEDILOL, MONTELUKAST, CITALOPRAM, GLICLAZIDE, CEFACLOR, EZETIMIBE, ROFECOXIB, QUETIAPINE FUMARATE, METFORMIN HCL, ACARBOSE, CHLORPHENIRAMINE MALEATE, NATEGLINIDE, LEFLUNOMIDE, VALSARTAN, CEFAZOLIN SODIUM, DIACEREIN, PAROXETINE, LEVOFLOXACIN, LEVETIRACETAM, ZOLMITRIPTAN, GLIBENCLAMIDE, TIZANIDINE, PERINDOPRIL ERBUMINE, RAMIPRIL, CEFTAZIDIME, CEFUROXIME AXETYL, THIOCOLCHICOSIDE, ACAMPROSATE, ACETYLCYSTEINE, ALPHA CALCIDOL, ALPHA LIPOIC ACID, ARIPIPRAZOLE, ATOMOXETINE, BALSALAZIDE DISODIUM, BUTENAFINE HCL, CALCITRIOL, CARBONYL IRON, FOLIC ACID, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, CEFDINIR, CEFEPIME HCL, CEFIXIME, CEFPODOXIME PROXETIL, CEFPROZIL, CEPHALEXINE MONOHYDRATE, CICLESONIDE, CILAZAPRIL, CILOSTAZOL, CINITAPRIDE, CITICOLINE, CO-ENZYME Q10, DARIFENASIN, DEFERIPRONE, DOTHIEPIN, DULOXETINE, ELETRIPTAN, ESCITALOPRAM, ESOMEPRAZOLE, ETORICOXIB, FELODIPINE, FENOFIBRATE, FERROUS SULPHATE, ZINC SULPHATE, FLUVASTATIN, FROVATRIPTAN, GABAPENTIN, GALANTAMINE, GEMIFLOXACIN, GINKGO BILOBA, GLIMEPRIDE, GRANISETRON, IBANDRONATE, IRBESARTAN, IRON HYDROXIDE POLYMALTOSE, LAMIVUDINE, LAMOTRIGINE, LEVETIRACETAM, LETROZOLE, LINEZOLIDE, MEMANTINE HCL, METOPROLOL, MIDODRINE, MIRTAZAPINE, MIZOLASTINE, MOSAPRIDE CITRATE DIHYDRATE, MYCOPHENOLATE MOFETIL, NEBIVOLOL, NEFAZODONE, NIACIN, NITAZOXANIDE, ONDANSETRON, ORNIDAZOLE, OXCARBAZEPINE, PIMECROLIMUS, PRAVASTATIN, PREGABALIN, RABEPRAZOL, REBAMIPIDE, REPAGLINIDE, RISEDRONATE, RISPERIDONE, RIVASTIGMINE, ROSUVASTATIN, SACCHAROMYCES BOULARDII, TACROLIMUS, TADALAFIL, TAMSULOSIN HCL, TAZAROTEN, TAZOBACTAM SODIUM, PIPERACILLIN SODIUM, TEGASEROD, TELITHROMYCIN, TERAZOCIN, TERIPARATIDE, TOLTERODINE TARTRATE, TOPIRAMATE, TRANDOLAPRIL, TRIMETHAZIDINE, VALACYCLOVIR, VALPROATE SODIUM, VENLAFAXINE, VORICONAZOLE, XIMELAGATRAN, ZALEPLON, ZIPRASIDONE, ZOLEDRONIC ACID | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
- Other trademarks owned by SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
- Other trademarks owned by SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI
- Other trademarks in Class 005
- Similar marks named SANOVEL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 28, 2021 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Nov 28, 2021 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jan 25, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 1, 2015 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 27, 2014 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Aug 27, 2014 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| May 13, 2014 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 13, 2013 | C71T | CANCELLED SECTION 71 | — |
| Nov 3, 2012 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jun 2, 2011 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jun 5, 2008 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 7, 2007 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 7, 2007 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 7, 2007 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 10, 2006 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 3, 2006 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 20, 2006 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 20, 2006 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 14, 2006 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 9, 2006 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Feb 21, 2006 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 24, 2006 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 4, 2006 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 7, 2005 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 2, 2005 | ALIE | ASSIGNED TO LIE | — |
| Nov 28, 2005 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 27, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 14, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 14, 2005 | PAPER RECEIVED | — | |
| Jun 20, 2005 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 14, 2005 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 11, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 11, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 18, 2005 | NWAP | NEW APPLICATION ENTERED | — |
| Feb 17, 2005 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |